Cipla has announced its unaudited financial results for the quarter ended September 30, 2012 (Q2).
Gross revenues grew by 23.6 per cent to Rs 2220 crore, operating margins grew by 57.7 per cent to Rs 677 crore and profit after tax grew by 61.8 per cent to Rs 500 crore during Q2 FY 12-13.
Domestic revenues grew by 13.5 per cent to Rs 962 crore during Q2 FY 12-13. The growth in domestic revenues was largely on account of growth in anti-asthma, anti-biotics and cardiovascular therapy segments.
EP News Bureau